San Francisco, CA – December 12, 2023 – A groundbreaking new study, published today in the prestigious journal JAMA and presented concurrently at the San Antonio Breast Cancer Symposium, is poised to fundamentally transform breast cancer screening guidelines. Challenging decades of conventional wisdom, the WISDOM study suggests that a personalized approach, meticulously tailored to a woman’s individual risk profile, offers a safer and more effective alternative to the prevailing "one-size-fits-all" model of routine annual mammograms. Researchers found that by aligning screening frequency and modality with personal risk levels, it was possible to significantly reduce the diagnosis of advanced cancers while ensuring individuals receive the most appropriate level of surveillance.
This monumental finding, stemming from the initial phase of the WISDOM study involving 46,000 women across the United States, signals a pivotal departure from age-centric screening protocols. Instead, it advocates for a sophisticated system rooted in comprehensive risk evaluation, integrating a multitude of factors far beyond mere chronological age. The University of California, San Francisco (UCSF) served as the coordinating center for this ambitious multi-institutional endeavor, which promises to reshape the landscape of preventive breast health.
Main Facts: A New Era of Precision Screening
The core revelation of the WISDOM study is a compelling argument for individualized breast cancer screening. By assessing a woman’s unique risk, researchers demonstrated that screening could be optimized to prevent late-stage diagnoses without over-screening low-risk individuals or underscreening those at high risk. This personalized strategy, developed and rigorously tested by the WISDOM consortium, incorporated genetic, biological, and lifestyle factors, along with health history and breast density, to categorize participants into distinct risk groups. Each group then received tailored recommendations for screening frequency and type.
A key outcome was the observed efficiency and efficacy of this risk-based approach. The study found no increase in the rate of late-stage cancer diagnoses among women following personalized screening schedules compared to those adhering to traditional annual mammography. Furthermore, a substantial majority—89% of women in an observational arm who chose their screening strategy—opted for the risk-based approach, indicating strong patient acceptance and confidence in the personalized model. The implications are profound, suggesting not only improved clinical outcomes but also a more judicious allocation of healthcare resources, redirecting intensive screening efforts towards those who stand to benefit most.
Chronology: From Concept to Clinical Transformation
The journey of the WISDOM study, an acronym for Women Informed to Screen Depending On Measures of Risk, began with a visionary premise: to directly compare the efficacy of personalized, risk-based screening against the standard of care.
The Inception (2016)
The study officially launched in 2016, driven by a growing recognition within the medical community that the long-standing age-based screening guidelines were inherently imperfect. For decades, the dominant paradigm recommended annual mammograms for most women starting at age 40 or 50, based on population-level averages. However, scientific advancements in genetics, imaging, and epidemiology increasingly highlighted the vast heterogeneity of breast cancer risk. Dr. Laura J. Esserman, MD, MBA, director of the UCSF Breast Care Center and the study’s first author, championed the idea of moving beyond this antiquated model. Her vision was to harness comprehensive individual data to craft more precise and effective screening strategies. The study was designed as a pragmatic, randomized clinical trial, a gold standard in medical research, to provide robust evidence for this paradigm shift.
Phase One Enrollment and Methodology
The initial phase of the WISDOM study rapidly enrolled 46,000 women across diverse sites in the United States. Participants were offered a choice: either be randomized to receive either traditional annual screening or personalized, risk-based screening, or join an observational group where they could choose their preferred strategy. This flexible design was crucial for understanding both the clinical outcomes and patient preferences.
The personalized arm utilized well-validated risk models to categorize women. These models were not simple checklists but sophisticated algorithms that weighed numerous variables to generate a comprehensive risk score. This phase laid the groundwork for collecting the extensive data—including genetic samples, lifestyle questionnaires, and detailed health histories—that would inform the risk stratification.
The Expansion (Post-2016)
Following its initial success and robust enrollment, the WISDOM study expanded its scope, ultimately enrolling more than 80,000 women. A significant development in this expansion was the inclusion of younger women, specifically those as young as 30. This strategic inclusion was vital for identifying individuals who might face an elevated risk of aggressive early-onset cancers due to inherited genetic variants, a population often overlooked by traditional age-based screening guidelines. This expansion underscored the study’s commitment to a truly comprehensive and inclusive approach to risk assessment.
Publication and Presentation (December 2023)
The culmination of years of meticulous data collection and analysis arrived on December 12, 2023, with the simultaneous publication of the study’s findings in JAMA and presentation at the prestigious San Antonio Breast Cancer Symposium. This dual announcement signaled the gravity and transformative potential of the research, ensuring its immediate dissemination to both the broader medical community and the public. The findings unequivocally demonstrated the viability and benefits of personalized breast cancer screening, providing the evidence base for a long-awaited transformation in clinical practice.
Looking Ahead: WISDOM 2.0
The journey doesn’t end here. Researchers are already forging ahead with WISDOM 2.0, a follow-up study that aims to further refine risk assessment models. This next phase is designed to enhance the ability to identify women at higher likelihood of developing aggressive breast cancers, ensuring they receive even more precisely tailored screening and prevention strategies aligned with their long-term health needs. The continuous evolution of this research underscores the dynamic nature of personalized medicine and the ongoing commitment to optimizing breast cancer care.
Supporting Data: The Mechanics of Personalized Screening
The WISDOM study’s strength lies in its meticulous methodology and the compelling data it generated, which collectively dismantle the rationale for generic screening guidelines.
The Flaws of Age-Based Screening
For decades, breast cancer screening guidelines have largely relied on age as the primary determinant for initiating and continuing mammography. This approach, while simple to implement, has inherent limitations. It assumes a relatively uniform risk profile across broad age cohorts, an assumption that scientific evidence has increasingly challenged. As Dr. Esserman highlighted, "Breast cancer risk can vary greatly from one person to another." The consequence of age-alone screening is often two-fold: over-screening for women at genuinely low risk, leading to unnecessary anxiety, false positives, and biopsies; and critically, under-screening for younger women or those with significant risk factors who may develop aggressive cancers before they reach the "recommended" screening age.
The WISDOM Study’s Comprehensive Risk Model
To overcome these limitations, the WISDOM study directly compared traditional annual mammography with a screening strategy built on individual risk assessment. Utilizing advanced, well-validated risk models, researchers integrated five key categories of information to stratify participants:
- Age: While not the sole factor, age remains a component, as risk generally increases with age. However, its influence is balanced by other, more specific risk indicators.
- Genetic Information: Beyond well-known pathogenic variants like BRCA1 and BRCA2, the study broke new ground by evaluating smaller DNA changes that can be combined into a polygenic risk score (PRS). This innovative approach significantly improved the precision of risk predictions, leading to 12% to 14% of participants being reassigned to a different risk category based on their PRS. A particularly striking finding was that 30% of women who tested positive for a genetic variant linked to higher breast cancer risk reported no family history of the disease. Under current clinical guidelines, many of these women would not typically qualify for genetic testing, highlighting a critical gap the personalized approach addresses.
- Lifestyle Factors: These included modifiable elements such as diet, physical activity levels, alcohol consumption, and body mass index (BMI). These factors, though individually small, contribute collectively to a woman’s overall risk profile.
- Health History: Past medical events, such as benign breast biopsies (e.g., atypical hyperplasia), prior radiation exposure, and reproductive history (e.g., age at first menstruation, parity, age at first live birth), significantly influence breast cancer risk.
- Breast Density: Denser breast tissue not only increases the risk of breast cancer but also makes cancers harder to detect on a mammogram, necessitating potentially different screening modalities.
Tailored Screening Recommendations by Risk Group
Based on the comprehensive risk evaluation, participants were grouped into four distinct categories, each receiving specific screening guidance:
- Lowest Risk (26% of participants): These women were advised to delay screening until age 50 or until an algorithm indicated their risk had naturally reached that of a typical 50-year-old woman. This approach avoids unnecessary early screening for a quarter of the population.
- Average Risk (62% of participants): The majority of women in this group were advised to undergo screening every two years, a frequency often recommended for average-risk women in some national guidelines, but here applied specifically after a detailed risk assessment.
- Elevated Risk (8% of participants): For these women, annual mammograms were recommended, ensuring consistent surveillance for a higher-risk demographic.
- Highest Risk (2% of participants): This small but critical group received the most intensive screening, advised to receive screening twice a year, alternating between mammography and magnetic resonance imaging (MRI), regardless of age. MRI is known for its higher sensitivity in dense breasts and for detecting cancers in high-risk individuals.
Personalized Prevention Strategies
Beyond tailored screening, the WISDOM study extended its personalized approach to prevention for women identified with elevated or highest risk. These participants received customized guidance aimed at actively lowering their chances of developing breast cancer. This support included access to an online decision-making tool focused on breast health, direct contact with a breast health specialist, and recommendations spanning lifestyle changes (e.g., improving diet, increasing physical activity) and discussions about risk-reducing medications (e.g., tamoxifen, raloxifene). This holistic approach empowers women to take proactive steps based on their individual risk profile.
Outcomes and Patient Acceptance
Crucially, the personalized screening approach did not lead to a higher rate of late-stage cancer diagnoses, directly refuting concerns that less frequent screening for lower-risk groups might result in missed cancers. This finding underscores the safety and efficacy of the risk-based model. Furthermore, the strong acceptance among the observational group, with 89% opting for risk-based screening, suggests that women are not only open to but actively prefer a more personalized and informed approach to their health. This high uptake rate is a powerful indicator of the potential for widespread adoption in clinical practice.
Official Responses: A Call to Transform Clinical Guidelines
The study’s findings have elicited strong responses from its lead investigators, who emphasize the urgent need for a paradigm shift in breast cancer screening.
Dr. Laura J. Esserman, the study’s first author and a leading voice in breast cancer research, articulated the transformative potential with conviction: "These findings should transform clinical guidelines for breast cancer screening and alter clinical practice." She further elaborated on the foundational element of this new approach: "The personalized approach begins with risk assessment, incorporating genetic, biological, and lifestyle factors, which can then guide effective prevention strategies." Dr. Esserman’s comments underscore the comprehensive nature of the proposed change, moving beyond mere screening frequency to encompass a broader spectrum of preventive care. Her call for transformation is not merely an academic suggestion but a direct challenge to established medical norms, reflecting the robust evidence generated by WISDOM.
Co-author Dr. Jeffrey A. Tice, a UCSF professor of Medicine specializing in breast cancer risk assessment tools, highlighted the practical advantages and resource optimization inherent in the personalized model. "Shifting resources from lower-risk women to higher-risk women is an efficient, effective approach to screening for and preventing breast cancer," Dr. Tice stated. His observation points to the dual benefit of personalized screening: improved outcomes for individuals and a more sustainable, equitable allocation of finite healthcare resources. In an era of escalating healthcare costs, the efficiency aspect of the WISDOM findings is particularly compelling for health policy makers and insurance providers.
Allison S. Fiscalini, MPH, of UCSF, director of the Athena Breast Health Network and the WISDOM study, emphasized the profound impact of the study’s expanded genetic testing strategy. "This is one of the first studies to offer genetic testing to all women, regardless of family history," Fiscalini noted. She further elaborated on the potential implications: "When used as part of a comprehensive risk assessment, these results could have a real impact on improving the safety and effectiveness of screening and prevention." Fiscalini’s comments highlight a critical public health implication: the ability to identify a significant proportion of women with genetic predispositions who would otherwise be missed by current, family-history-dependent genetic testing criteria. This aspect alone represents a monumental step forward in early identification and risk management.
Implications: Reshaping the Future of Breast Cancer Care
The WISDOM study’s findings carry far-reaching implications that extend beyond individual patient care, promising to reshape clinical guidelines, public health strategies, and the very philosophy of preventive medicine.
Transforming Clinical Guidelines and Practice
The most immediate and direct implication is the call to revise existing breast cancer screening guidelines. Organizations like the American Cancer Society, the U.S. Preventive Services Task Force (USPSTF), and others will now face compelling evidence to re-evaluate their age-based recommendations. A shift towards personalized, risk-based screening would necessitate significant changes in clinical practice. Primary care physicians and gynecologists, who are often the first point of contact for screening discussions, would require enhanced training in risk assessment methodologies. This could involve integrating sophisticated risk calculators into electronic health records and facilitating access to genetic counseling and testing services for a broader population. The current system, often reliant on simple age cut-offs, would evolve into a more nuanced, individualized dialogue between patient and provider, focusing on a woman’s unique risk profile.
Optimizing Resource Allocation and Reducing Harms
One of the study’s most powerful implications is the potential for optimized resource allocation. By shifting intensive screening efforts (e.g., annual mammograms, MRI) to the 10% of women at elevated or highest risk, and reducing screening frequency for the 26% at lowest risk, healthcare systems can operate more efficiently. This reallocation not only saves costs associated with unnecessary screening tests but also mitigates the harms of overdiagnosis and overtreatment. Overdiagnosis, where cancers are detected that would never have become life-threatening, can lead to unnecessary surgeries, radiation, and chemotherapy, with significant psychological and physical tolls on patients. The WISDOM study offers a pathway to reduce these harms while simultaneously enhancing detection for those truly in need.
Expanding Access to Genetic Information
The revelation that 30% of women with high-risk genetic variants had no family history of breast cancer is particularly profound. Current guidelines often limit genetic testing to individuals with a strong family history, leading to missed opportunities for early intervention for a substantial segment of the population. The WISDOM study strongly advocates for offering genetic testing to all women as part of a comprehensive risk assessment. This expanded access would empower more women with crucial information about their inherited risk, enabling proactive screening and prevention strategies, including potentially considering risk-reducing medications or prophylactic surgeries for the highest-risk individuals. This democratizes access to vital genetic health information, moving beyond a reactive, family-history-dependent model.
Empowering Patients Through Personalized Prevention
The study’s focus on personalized prevention strategies for higher-risk women represents a significant step towards patient empowerment. Providing access to online decision-making tools and direct contact with breast health specialists fosters a collaborative approach to health management. Women are not merely recipients of screening recommendations but active participants in their own care, armed with knowledge about modifiable lifestyle factors and medical options to mitigate their individual risk. This holistic approach aligns with the growing trend of patient-centered care, emphasizing shared decision-making and individual agency.
Addressing Health Equity
While the WISDOM study offers immense promise, its implementation also raises important considerations regarding health equity. Ensuring equitable access to comprehensive risk assessment tools, genetic testing, and advanced imaging modalities (like MRI) will be crucial. Disparities in healthcare access, socioeconomic status, and insurance coverage could potentially exacerbate existing inequities if not proactively addressed during the transition to personalized screening. Policymakers and healthcare providers must work to ensure that the benefits of this advanced approach are available to all women, regardless of their background or geographic location.
The Path Forward: WISDOM 2.0 and Beyond
The ongoing WISDOM 2.0 study signifies the continuous evolution of this research. By refining risk assessment, particularly for aggressive breast cancers, researchers aim to further enhance the precision of screening and prevention. This iterative process is characteristic of scientific advancement, where initial findings pave the way for deeper understanding and more sophisticated interventions. The WISDOM study has laid a robust foundation for a future where breast cancer screening is not a uniform mandate but a highly individualized, data-driven strategy, ultimately leading to better health outcomes and a more efficient healthcare system for all women.
Co-Authors: From UCSF, authors include Laura J. van ‘t Veer, PhD; Maren T. Scheuner MD; Alexander D. Borowsky, MD; Amie M. Blanco, MD; Katherine S. Ross, MS; Barry S. Tong, MS; Diane Heditsian; Susie Brain; Vivian Lee; Kelly Blum, MS; Mi-Ok Kim, PhD; Leah P. Sabacan, MBA; Kirkpatrick B. Fergus, MD; Christina Yau, PhD; Celia Kaplan, DrPH; Suzanne Elder, CFNP; Kelly Adduci, MPH; Jeffrey B. Matthews, PhD; Robert A. Hiatt, MD, PhD; Elad Ziv, MD; and Jeffrey A. Tice, MD.
Other investigators are at UC Los Angeles; UC Irvine; UC San Diego; San Francisco VA Health Care System; Sanford Health in North Dakota; University of Chicago; Diagnostic Center of Miami; University of Alabama; Virginia Commonwealth University; Weill Cornell Medicine in New York; and the Karolinka Institutet in Stockholm.
Funding: Study support included the Patient Center Outcomes Research Institute, the National Cancer Institute (R01CA237533), and the Breast Cancer Research Foundation. Please see the paper for other funding sources.
Conflicts of Interest: Esserman is a medical advisory panel member for Blue Cross Blue Shield and has received author fees from the UpToDate electronic medical information resource. Please see the paper for disclosures of other investigators.
About the Author
